Thu, May 16, 9:01 PM (243 days ago)
Exicure, Inc. filed its Form 10-Q for the quarter ended September 30, 2023, highlighting significant challenges and uncertainties. The company reported a net loss of $5.3 million for the quarter and $15.4 million for the nine months ended September 30, 2023, compared to $5.2 million and $21.0 million, respectively, for the same periods in 2022. Revenue dropped to zero due to the termination of collaboration agreements with Ipsen and AbbVie. Operating expenses decreased significantly due to the suspension of research and development activities following a strategic shift in September 2022. Exicure's cash and cash equivalents were $0.9 million as of September 30, 2023, down from $8.6 million at the end of 2022. The company faces substantial doubt about its ability to continue as a going concern, needing significant additional funding in the near term. Exicure is exploring strategic alternatives, including potential partnerships or transactions in industries unrelated to its historical operations. The company also faces potential delisting from Nasdaq due to non-compliance with listing requirements, including minimum bid price and stockholders' equity thresholds.